News & Updates
Filter by Specialty:
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
07 Jul 2023
In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
07 Jul 2023
COVID outcomes worse in polluted cities
01 Jul 2023
byElvira Manzano
More evidence suggests that people exposed to more air pollution during the pandemic are at greater risk for COVID-19 infection, hospitalization, and death, but the exact mechanism behind the link is unknown.
COVID outcomes worse in polluted cities
01 Jul 2023
Updated CodeBreak 200 analyses boost sotorasib role in KRASG12C-mutant NSCLC
19 Jun 2023
byAudrey Abella
In the PRO analyses of the phase III CodeBreak 200 trial, the first-in-class KRASG12C inhibitor sotorasib improved quality of life (QoL) of patients with pretreated KRASG12C-mutated advanced non-small-cell lung cancer (NSCLC) compared with docetaxel.
